| Ulcerative Colitis
Stelara vs Yusimry
Side-by-side clinical, coverage, and cost comparison for ulcerative colitis.Deep comparison between: Stelara vs Yusimry with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsYusimry has a higher rate of injection site reactions vs Stelara based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Yusimry but not Stelara, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Stelara
Yusimry
At A Glance
SC injection
Every 8-12 weeks
IL-12/23 antagonist
SC injection
Every 1-2 weeks
TNF-alpha inhibitor
Indications
- Psoriasis vulgaris
- Arthritis, Psoriatic
- Crohn Disease
- Ulcerative Colitis
- Rheumatoid Arthritis
- Juvenile arthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Crohn Disease
- Ulcerative Colitis
- Psoriasis vulgaris
- Hidradenitis Suppurativa
- Uveitis
Dosing
Psoriasis vulgaris Adults <=100 kg: 45 mg SC at weeks 0 and 4, then every 12 weeks; adults >100 kg: 90 mg SC at weeks 0 and 4, then every 12 weeks; pediatric patients >=6 years: weight-based dosing (0.75 mg/kg for <60 kg, 45 mg for 60-100 kg, 90 mg for >100 kg) SC at weeks 0 and 4, then every 12 weeks.
Arthritis, Psoriatic Adults: 45 mg SC at weeks 0 and 4, then every 12 weeks (90 mg for >100 kg with co-existent moderate-to-severe plaque psoriasis); pediatric patients >=6 years: weight-based dosing (0.75 mg/kg for <60 kg, 45 mg for >=60 kg, 90 mg for >100 kg with co-existent plaque psoriasis) SC at weeks 0 and 4, then every 12 weeks.
Crohn Disease, Ulcerative Colitis Adults: single IV induction dose (260 mg for <=55 kg, 390 mg for >55-85 kg, 520 mg for >85 kg), followed by 90 mg SC at week 8, then every 8 weeks.
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg SC every other week; in Rheumatoid Arthritis without concomitant MTX, may increase to 40 mg every week or 80 mg every other week.
Juvenile arthritis 40 mg SC every other week for patients 2 years of age and older weighing 30 kg or greater.
Crohn Disease, Ulcerative Colitis 160 mg SC on Day 1 (or split over two consecutive days), 80 mg on Day 15, then 40 mg every other week starting Day 29.
Psoriasis vulgaris, Uveitis Initial 80 mg SC, then 40 mg every other week starting one week after the initial dose.
Hidradenitis Suppurativa 160 mg SC on Day 1 (or split over two consecutive days), 80 mg on Day 15, then 40 mg weekly or 80 mg every other week starting Day 29.
Contraindications
- Clinically significant hypersensitivity to ustekinumab or any excipient of STELARA
—
Adverse Reactions
Most common (>=1%) Nasopharyngitis, upper respiratory tract infection, headache, fatigue, back pain, dizziness, pharyngolaryngeal pain, pruritus, injection site erythema, myalgia, depression
Serious Infections, malignancies, serious hypersensitivity reactions, posterior reversible encephalopathy syndrome (PRES), noninfectious pneumonia
Postmarketing Hypersensitivity reactions (anaphylaxis, angioedema, dyspnea, rash, urticaria), lower respiratory tract infection, PRES, interstitial pneumonia, eosinophilic pneumonia, cryptogenic organizing pneumonia, pustular psoriasis, erythrodermic psoriasis, hypersensitivity vasculitis
Most common (>=5%) Injection site reactions, upper respiratory infection, sinusitis, headache, rash, nausea, abdominal pain, back pain, urinary tract infection, hyperlipidemia, hypercholesterolemia, accidental injury.
Serious Serious infections (pneumonia, septic arthritis, cellulitis, diverticulitis, pyelonephritis), malignancies, hypersensitivity reactions, hepatitis B reactivation, neurologic reactions, hematological reactions, heart failure, autoimmunity, liver enzyme elevations.
Postmarketing Diverticulitis, large bowel perforations, pancreatitis, liver failure, hepatitis, sarcoidosis, Merkel Cell Carcinoma, demyelinating disorders, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, systemic vasculitis, deep vein thrombosis.
Pharmacology
Ustekinumab is a human IgG1k monoclonal antibody that binds the p40 protein subunit shared by IL-12 and IL-23, blocking their interaction with the IL-12Rb1 receptor chain and thereby suppressing downstream inflammatory signaling involved in natural killer cell activation and CD4+ T-cell differentiation and activation.
TNF-alpha antagonist; adalimumab-aqvh is a recombinant human IgG1 monoclonal antibody that binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors, also lysing surface TNF-expressing cells in vitro in the presence of complement.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Stelara
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (11/12)
Yusimry
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Stelara
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (4/8)
Yusimry
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Stelara
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Yusimry
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$5/fillfill
Stelara withMe Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Yusimry.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
StelaraView full Stelara profile
YusimryView full Yusimry profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.